secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001831283-22-000059
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q2 net loss $42.4M; cash $349.4M; mavacamten China Phase 3 enrollment complete
--------------------------------------------------------------------------------

- Net loss of $42.4M in Q2 2022 vs. $100.4M loss in Q2 2021; R&D expenses fell to $28.6M.
- Cash balance $349.4M at June 30, 2022; runway projected into second half of 2024.
- Completed enrollment in China Phase 3 EXPLORER-CN trial of mavacamten; topline data mid-2023.
- Submitted NDAs: mavacamten in Singapore (oHCM) and infigratinib in Hong Kong (cholangiocarcinoma).
- Three additional registration-enabling programs (TP-03, NBTXR3, BBP-398) to begin in China by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000059/0001831283-22-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000059/lian-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer